Trial Profile
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Proof of concept; Therapeutic Use
- 12 Dec 2023 Results performing the first whole genome sequencing (WGS) analysis of treated HR-SMM (n=27) and comparing to (n=701) patients with NDMM from CoMMpass (NCT01454297), presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Follow-up data after all patients have completed lenalidomide maintenance to evaluate the durability of responses off therapy were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 08 Jul 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.